
ELIXIRR INTERNATIONAL PLC
("Elixirr", the "Company" or the "Group")
Update on Main Market Admission
Elixirr International plc (AIM:ELIX), an established, global award-winning challenger consultancy, is pleased to provide an update on its intended move to the Main Market.
As previously announced, the Elixirr Board has progressed with its plans to transition the Company from AIM to the Main Market - a natural step in its evolution as a high-growth listed business and a move which reflects the scale, maturity, and ambition of Elixirr. We are pleased to report that preparations are well underway, and we remain on track to complete this move.
We anticipate that admission to the Equity Shares (Commercial Companies) segment of the Official List and commencement of trading on the Main Market of the London Stock Exchange (the "Admission") will take place on 1 July 2025. At that point, the Group's existing listing on AIM will be cancelled. In line with this, Elixirr hereby formally gives notice of the intended cancellation of trading of its ordinary shares on AIM, in accordance with Rule 41 of the AIM Rules for Companies.
Admission is subject to the approval by the FCA of a prospectus and the ordinary shares being admitted by the FCA to the Official List and by the London Stock Exchange to trading on the Main Market. Admission is not conditional upon shareholder approval. Shareholders should note that the Group's shares will no longer be traded on AIM with effect from Admission and should consult their own professional advisers regarding the consequences of Admission.
Capital Markets Day
We are pleased to remind institutional investors and analysts that invitations are open to attend Elixirr's immersive Capital Markets Day, which will be held on the afternoon of Wednesday, 4th June 2025, at Elixirr's London office.
This event will offer valuable insight into the global Challenger Consultancy's growth strategy and ambitious plans, providing an opportunity to engage directly with the leaders of the business. Partners from across the global team will provide interactive sessions revealing some of the cutting-edge digital, data, tech and AI strategies and solutions they've built with clients, including their work with Meta and ongoing partnership to transform British Cycling's customer experience through data. For those interested in attending, please email investor-relations@elixirr.com
Enquiries:
For enquiries, please refer to our Investor Contacts page:
https://www.elixirr.com/investors/investor-contacts
Elixirr International plc
+44 (0)20 7220 5410
Stephen Newton, Chief Executive Officer
Graham Busby, Deputy Chief Executive Officer
Nick Willott, Chief Financial Officer and Company Secretary
investor-relations@elixirr.com
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)
+44 (0)20 7220 0500
Stephen Keys, Callum Davidson, Isaac Hooper (Corporate Finance),
Sunila De Silva (ECM)
Peel Hunt LLP (Joint Broker)
+44 (0)20 7418 8900
Neil Patel, Ben Cryer, Alice Lane, Kate Bannatyne
About Elixirr International plc
Elixirr is an award-winning global consulting firm working with clients across a diverse range of industries, markets and geographies. Founded in 2009, the firm set out to be the 'challenger consultancy' and do things differently than the large corporate consultancies dominating the industry: working openly and collaboratively with clients from start to finish, delivering outcomes based on innovative thinking, not methodology, and treating each client's business like their own. Elixirr has been quoted on the AIM market of the London Stock Exchange since 2020. In addition to strong organic growth, Elixirr has acquired seven boutique firms - Den Creative, Coast Digital, The Retearn Group, iOLAP, Responsum, Insigniam and Hypothesis - to grow the Group's capabilities, diversify the business, expand into new geographies and access new clients.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.